Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CRNX NASDAQ:ORIC NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$26.41+1.6%$22.42$19.69▼$28.35$4.52B0.81.68 million shs1.73 million shsCRNXCrinetics Pharmaceuticals$83.62+0.2%$38.57$25.83▼$83.63$8.82B0.232.10 million shs10.03 million shsORICOric Pharmaceuticals$10.94+0.4%$8.95$7.23▼$14.93$1.13B1.021.82 million shs880,400 shsVKTXViking Therapeutics$41.14+3.0%$32.37$22.96▼$43.15$4.78B0.662.71 million shs1.71 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.76%+3.17%+19.82%+15.20%+23.69%CRNXCrinetics Pharmaceuticals-0.05%+115.85%+149.37%+110.67%+184.27%ORICOric Pharmaceuticals+0.18%+0.09%+44.75%+5.01%+4.51%VKTXViking Therapeutics-5.15%+6.62%+36.66%+14.33%+32.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$26.41+1.6%$22.42$19.69▼$28.35$4.52B0.81.68 million shs1.73 million shsCRNXCrinetics Pharmaceuticals$83.62+0.2%$38.57$25.83▼$83.63$8.82B0.232.10 million shs10.03 million shsORICOric Pharmaceuticals$10.94+0.4%$8.95$7.23▼$14.93$1.13B1.021.82 million shs880,400 shsVKTXViking Therapeutics$41.14+3.0%$32.37$22.96▼$43.15$4.78B0.662.71 million shs1.71 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.76%+3.17%+19.82%+15.20%+23.69%CRNXCrinetics Pharmaceuticals-0.05%+115.85%+149.37%+110.67%+184.27%ORICOric Pharmaceuticals+0.18%+0.09%+44.75%+5.01%+4.51%VKTXViking Therapeutics-5.15%+6.62%+36.66%+14.33%+32.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$32.9424.73% UpsideCRNXCrinetics Pharmaceuticals 2.29Hold$78.27-6.39% DownsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2776.17% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60127.52% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, CRNX, ACAD, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/7/2026ACADACADIA Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $36.007/7/2026CRNXCrinetics Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.007/7/2026CRNXCrinetics Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$55.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform7/7/2026CRNXCrinetics Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$81.00 ➝ $85.00(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B4.22$0.89 per share29.53$7.25 per share3.64CRNXCrinetics Pharmaceuticals$18.07M487.96N/AN/A$9.71 per share8.61ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2012.0030.7118.8734.30%9.61%7.07%8/5/2026 (Estimated)CRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest ORIC, CRNX, ACAD, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026ACADACADIA Pharmaceuticals$0.06N/AN/AN/A$295.88 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.87 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48CRNXCrinetics PharmaceuticalsN/A18.6018.56ORICOric PharmaceuticalsN/A16.3316.33VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CRNXCrinetics Pharmaceuticals98.51%ORICOric Pharmaceuticals95.05%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%CRNXCrinetics Pharmaceuticals3.80%ORICOric Pharmaceuticals5.70%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableORIC, CRNX, ACAD, and VKTX HeadlinesRecent News About These CompaniesViking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength1 hour ago | fxempire.comFNovo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data4 hours ago | finance.yahoo.comBuyout Buzz Around VKTX Is Back: What's Fueling the Speculation?July 9 at 11:01 AM | zacks.com3 High Growth GLP-1 Biotech Winners to Buy in JulyJuly 9 at 8:56 AM | 247wallst.com3 High Growth GLP-1 Biotech Winners to Buy in JulyJuly 9 at 8:00 AM | 247wallst.comWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market TodayJuly 8 at 10:55 PM | finance.yahoo.comWhy Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market TodayJuly 8 at 6:51 PM | zacks.comPiper Sandler Sticks to Its Buy Rating for Viking Therapeutics (VKTX)July 8 at 5:54 PM | theglobeandmail.comViking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year RunJuly 8 at 12:52 PM | finance.yahoo.comWhy Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's NextJuly 8 at 7:33 AM | finance.yahoo.comHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?July 5, 2026 | fool.comIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are SayingJuly 4, 2026 | fool.comHere's Why Viking Therapeutics Stock Surged Higher in JuneJuly 3, 2026 | fool.comCantor Fitzgerald Remains a Buy on Viking Therapeutics (VKTX)July 3, 2026 | theglobeandmail.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 1, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 1, 2026 | zacks.comIs Viking Therapeutics Stock Going to $100?July 1, 2026 | fool.comNovo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?June 29, 2026 | zacks.comIs It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?June 29, 2026 | finance.yahoo.comIs It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?June 29, 2026 | zacks.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong TimeBy Leo Miller | June 24, 2026SpaceX’s Historic IPO Has Already Sparked a 2X ETF FrenzyBy Ryan Hasson | June 22, 2026MarketBeat Week in Review – 06/08 - 06/12By MarketBeat Staff | June 13, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026ORIC, CRNX, ACAD, and VKTX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$26.41 +0.41 (+1.58%) Closing price 04:00 PM EasternExtended Trading$26.15 -0.26 (-0.98%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Crinetics Pharmaceuticals NASDAQ:CRNX$83.62 +0.13 (+0.16%) Closing price 04:00 PM EasternExtended Trading$83.59 -0.03 (-0.04%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Oric Pharmaceuticals NASDAQ:ORIC$10.94 +0.04 (+0.37%) Closing price 04:00 PM EasternExtended Trading$10.59 -0.35 (-3.20%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Viking Therapeutics NASDAQ:VKTX$41.14 +1.18 (+2.95%) Closing price 04:00 PM EasternExtended Trading$41.27 +0.13 (+0.32%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
